tradingkey.logo

Bristol Myers' Sotyktu Shows Superiority Over Placebo in Phase 3 Psoriatic Arthritis Trial

ReutersJun 11, 2025 11:02 AM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROM PIVOTAL PHASE 3 POETYK PSA-1 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU (DEUCRAVACITINIB) COMPARED WITH PLACEBO IN ADULTS WITH PSORIATIC ARTHRITIS

  • BRISTOL-MYERS SQUIBB CO - SOTYKTU DEMONSTRATES CONSISTENT SAFETY PROFILE WITH NO NEW SAFETY SIGNALS

  • BRISTOL-MYERS SQUIBB CO - SOTYKTU ACHIEVES PRIMARY ENDPOINT WITH 54.2% ACR20 RESPONSE AT WEEK 16

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI